Compare BANC & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANC | TWST |
|---|---|---|
| Founded | 1941 | 2013 |
| Country | United States | United States |
| Employees | 1904 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | N/A | 2018 |
| Metric | BANC | TWST |
|---|---|---|
| Price | $19.24 | $70.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $21.83 | ★ $46.88 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $13.93 | $18.91 |
| Revenue Next Year | $8.03 | $15.07 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $13.24 | $23.30 |
| 52 Week High | $21.61 | $80.50 |
| Indicator | BANC | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 60.64 |
| Support Level | $16.30 | $41.85 |
| Resistance Level | $19.40 | N/A |
| Average True Range (ATR) | 0.39 | 4.84 |
| MACD | 0.03 | 0.89 |
| Stochastic Oscillator | 80.99 | 63.30 |
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.